Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
about
Targeted therapies and immunotherapy in non-small-cell lung cancerOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistancec-Met as a Target for Personalized TherapyCIViC databasePF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsResponse to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingStructural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKDiscovering and understanding oncogenic gene fusions through data intensive computational approachesTargeted Lung Cancer Treatments and Eye MetastasisA phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.Recent Advances in Targeting ROS1 in Lung Cancer.Cabozantinib for the treatment of kidney cancer.ROS1 fusions in cancer: a review.Resistance to Therapy.Cabozantinib for the treatment of renal cell carcinoma.Lung cancer as a paradigm for precision oncology in solid tumours.Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer.Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review."Neurological complications of new chemotherapy agents".Current Landscape of Targeted Therapy in Lung Cancer.Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.[Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer.Emerging resistance pathways in lung cancer: what has ROS-1 taught us?An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions
P2860
Q26738986-64E1816A-CEDC-4485-9921-6619A5B30290Q26768158-449205DE-FFC5-43A2-95B4-E3E0936EA970Q26775347-52FEEF7A-EB32-46E1-B664-1C87DDEC6103Q26775483-86795408-F8C7-46BA-816D-D731C37B468BQ27612411-43AA6E1F-9AD0-4D23-AE7B-37321CAA5D2FQ27853138-7DD6F575-5B25-4850-B176-75F8CCA325F2Q27853167-AA9FDF25-952B-4049-856F-3FEE72865872Q27853214-2C2643C1-BC5F-4D97-B81E-2EC1859EF8BCQ28083446-7771CB04-68BF-4874-9442-2A01AE77AE66Q31083417-85A62846-D8C4-4482-9780-D068C8D95F77Q33566410-EE0B1E56-0D1D-44B9-ABAA-19C1EF14C62CQ33599860-3DE7E3EF-CFF0-4A2D-BF3C-98A50007271EQ33911863-35799CE3-7B48-4889-A3FD-CA7AA83962C1Q36066539-70592E5D-67FB-4203-9BD4-4952CAE46DD9Q36902114-C9C5A4B4-782D-442C-A764-6D4DC30B1FAEQ37003218-D19265F6-9B62-4BCA-BC23-BC3D69B47B5DQ37353957-AA5EDC2C-953E-4A74-87EA-0683666BE07CQ38640765-57453F0E-D92D-48B3-A932-E00B96C219BBQ38668871-AD9A8ABD-B248-449B-AA27-3717A4D1A9D6Q38852070-CA501D5B-E962-4DD6-860F-04248BCA3868Q38930367-A83A02B6-19D1-4077-A77F-93F558F1AFD9Q39005403-3CDD3E18-021D-4D4C-ACB4-7C63FF5BF2D2Q39449763-78988921-6108-4036-929D-618E6895C300Q39930964-10051F09-B2A5-4EEC-AB47-103C3E64799FQ41659344-EBC51926-7E67-4396-93A2-05DA3B509142Q44507827-BF43596E-569B-4F22-9E87-3C9608B0384BQ45069581-5C35D170-A9E2-484C-BE10-25D4618BE284Q46034707-34563557-8A97-4565-BD35-8028F0785B53Q47351169-A8AD1166-434B-4481-BDB7-DAC49CB0DDEBQ47599265-FF65A78A-13DD-4B51-9326-435330E3F28BQ49887919-6F5449CE-5282-4689-816A-FB3F388A5D17Q50251062-BF3F4F28-9985-4F78-8DAB-13CCD94C103CQ52312436-B148BB61-5EC3-4072-80F1-DB0946A1CEC3Q52720230-C04490DB-3DC4-4AF1-B7F5-CE710B37776DQ53565079-CB36E46C-66C3-40CC-9BD1-2D9C8C20993EQ54980900-66DAA5F9-72B9-4CA1-B47E-D98F0A5A5E47Q55189638-79E5268C-6A30-4900-96CA-2C06F16BDDA4Q55258220-80633A63-3365-402C-8B97-35BB6C035BE2Q55515425-66BB8929-EDAB-438D-A5F9-7E59BE9902CBQ58749346-7FA6B1D9-83E3-445B-A32A-BE57D586E24A
P2860
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
@ast
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
@en
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
@nl
type
label
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
@ast
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
@en
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
@nl
altLabel
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
@en
prefLabel
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
@ast
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
@en
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
@nl
P2093
P2860
P3181
P1476
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
@en
P2093
Alice T Shaw
Elizabeth L Lockerman
Jeffrey A Engelman
Naoya Fujita
Sumie Koike
Yuka Kobayashi
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-14-1385
P407
P577
2015-01-01T00:00:00Z